BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Variant surface antigen 2 chondroitin sulphate A (VAR2CSA); chondroitin sulfate proteoglycans (CSPG)

December 17, 2015 8:00 AM UTC

Patient sample, cell culture and mouse studies suggest VAR2CSA conjugated to cytotoxic agents could help treat cancer. In patients with various types of epithelial cancers, bone sarcomas or soft tissu...